Facing Pricing Pressure And Generic Erosion, Simcere Shifts To Innovative Products For Future Growth: China Earnings Roundup (Part I)
This article was originally published in PharmAsia News
Executive Summary
China’s healthcare industry saw slower growth in the third quarter. In a recurring feature, PharmAsia News combs through earnings reports to bring you highlights of China’s leading pharma companies and how their efforts affect different sectors of the industry.